A Randomized Phase I Study to Assess the Pharmacokinetics, Tolerability, Efficacy and Pharmacodynamics of Three Dosing Schedules of Oral Rigosertib in Transfusion-dependent, Low, Intermediate 1, or Intermediate-2 Myelodysplastic Syndrome Patients Based on the International Prognostic Scoring System
Phase of Trial: Phase I
Latest Information Update: 09 May 2017
At a glance
- Drugs Rigosertib (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Onconova Therapeutics
- 02 May 2017 Planned End Date changed from 1 Oct 2017 to 1 Oct 2018.
- 02 May 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2018.
- 14 Apr 2016 Planned End Date changed from 1 Sep 2016 to 1 Oct 2017.